A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

被引：48

作者：

Riedell, Peter A. ^{[1
]}

Walling, Chase ^{[2
]}

Nastoupil, Loretta J. ^{[3
]}

Pennisi, Martina ^{[4
]}

Maziarz, Richard T. ^{[5
]}

McGuirk, Joseph P. ^{[6
]}

Oluwole, Olalekan O. ^{[7
]}

Bachanova, Veronika ^{[8
]}

Hwang, Wei-Ting ^{[9
]}

Schuster, Stephen J. ^{[10
]}

Perales, Miguel-Angel ^{[4
]}

Bishop, Michael R. ^{[1
]}

Porter, David L. ^{[2
]}

机构：

[1] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA

[2] Univ Penn, Div Hematol & Oncol, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[4] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA

[5] Oregon Hlth & Sci Univ, Ctr Hematol Malignancies, Portland, OR 97201 USA

[6] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS 66103 USA

[7] Vanderbilt Univ, Med Ctr, Div Hematol Oncol, Nashville, TN USA

[8] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA

[9] Univ Penn, Perelman Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA

[10] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA

来源：

关键词：

D O I：

10.1182/blood-2019-127490

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1599

引用

页数：5